Irritable Bowel Syndrome Treatment Market Size in the 7MM was ~USD 2000 Million in 2023, estimated DelveInsight

Irritable Bowel Syndrome Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Irritable Bowel Syndrome Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

DelveInsight's "Irritable Bowel Syndrome Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Irritable Bowel Syndrome, historical and forecasted epidemiology as well as the Irritable Bowel Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock detailed insights into the Irritable Bowel Syndrome Market by downloading the comprehensive report from DelveInsight @ Irritable Bowel Syndrome Treatment Market Size [https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Irritable Bowel Syndrome Market Report

* The rise in the geriatric population, the increase in the prevalence of gastrointestinal diseases and disorders such as alteration of bowel habits and abdominal pain, the surge in level of stress, and unhealthy diet are the major factors that drive the growth of the irritable bowel syndrome treatment market.
* As per the American College of Gastroenterology (2023), irritable bowel syndrome is common and affects about 5% of the population or about 1 in 20 people in the US.
* As per Cleveland Clinic (2023), it has been estimated that about 1015% of the adult population in the United States have irritable bowel syndrome. However, only 57% receive an irritable bowel syndrome diagnosis. It is the most common disease that gastroenterologists diagnose.
* As per Breen-Lyles et al. (2023), the mean irritable bowel syndrome symptom severity score in Rome IV patients was significantly higher than in Rome III criteria.
* As per Jean-Marc et al. (2023), the severity-specific prevalence of irritable bowel syndrome in France was 31.3% for the moderately severe form and 68.7% for the severe form.
* The leading Irritable Bowel Syndrome Companies such as Redhill Biopharma, Forest Pharmaceuticals, Inc., Bausch Health , and others.
* Promising Irritable Bowel Syndrome Therapies such as Rifaximin, eluxadoline, lubiprostone, linaclotide , and others.

Gain a competitive edge in the Irritable Bowel Syndrome Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Irritable Bowel Syndrome Treatment Drugs [https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Irritable Bowel Syndrome Epidemiology Segmentation in the 7MM

* Total Irritable Bowel Syndrome Prevalent Cases
* Total Irritable Bowel Syndrome Diagnosed Cases
* Irritable Bowel Syndrome Gender-specific Cases
* Irritable Bowel Syndrome Severity-specific Cases
* Irritable Bowel Syndrome Subtype-specific Cases
* Total Irritable Bowel Syndrome Treated Cases

Irritable Bowel Syndrome Market Insights

Irritable bowel syndrome (IBS) is a complex disorder characterized by motility dysfunction, visceral hypersensitivity, and various contributing factors including genetics, diet, and immune activation. Its diagnosis and management pose significant challenges globally. IBS manifests in diverse forms, classified by predominant stool texture, and imposes a substantial burden on healthcare systems worldwide. In the United States alone, direct medical costs associated with IBS reach up to USD 10 billion annually, exacerbated by high healthcare resource utilization and regional disparities in testing and treatment approaches.

Discover key developments and opportunities in the Irritable Bowel Syndrome Market. Click here to learn more from DelveInsight's latest report @ Irritable Bowel Syndrome Market Size [https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Irritable Bowel Syndrome Marketed Drugs

* VIBERZI/TRUBERZI (eluxadoline): Abbvie

VIBERZI (eluxadoline) is a new class of medication acting on local receptors in the gastrointestinal tract. It improves diarrhea and abdominal pain by interacting with mu- and delta opioid receptors in the intestine to slow gastrointestinal motility and reduce visceral pain. Activation of the mu-receptor reduces diarrhea, while antagonism of the delta-receptor enhances the analgesic activity and reduces the risk of constipation.

* LINZESS/CONSTELLA (linaclotide): Ironwood Pharmaceuticals/ Abbvie/ Astellas Pharma

Linaclotide is a guanylate cyclase-C agonist that is thought to work in two ways based on nonclinical studies. It binds to the guanylate cyclase-C receptor locally within the intestinal epithelium. Activation of guanylate cyclase-C results in increased intestinal fluid secretion, accelerated transit, and a decrease in the activity of pain-sensing nerves in the intestine. In the United States, Ironwood and AbbVie co-develop and co-commercialize LINZESS to treat adults with IBS-C. In Europe, AbbVie markets linaclotide under the brand name CONSTELLA for treating adults with moderate-to-severe IBS-C.

Irritable Bowel Syndrome Emerging Drugs

* BEKINDA (RHB-102): RedHill Biopharma

RHB-102 is an investigational, once-daily, bi-modal release, oral formulation of ondansetron, a leading member of the family of 5-HT3 serotonin receptor inhibitors intended to treat nausea, vomiting, and diarrhea symptoms experienced in some people suffering from acute gastroenteritis, gastritis, and irritable bowel syndrome with diarrhea (IBS-D).

* Blautix (MRx1234): 4D pharma

Blautix (MRx1234) is a single-strain live biotherapeutic product (LBP), being developed as a treatment for both IBS-C and IBS-D and has the potential to become the first-ever disease-modifying therapy suitable for all irritable bowel syndrome patients regardless of clinical subtype. Blautix has a unique metabolism, consuming hydrogen and producing acetate, which promotes bacterial cross-feeding of the microbiota increasing diversity and stability, two attributes that have been demonstrated to be decreased in patients with irritable bowel syndrome compared to healthy controls.

Irritable Bowel Syndrome Therapeutics Market

There are five drugs approved for irritable bowel syndrome in the United States, namely VIBERZI (eluxadoline), LINZESS (linaclotide), IBSRELA (tenapanor), TRULANCE (plecanatide), and XIFAXAN (rifaximin). Market access and reimbursement options can differ depending on regulatory status, the size of the target population, the setting of care, unmet needs, the magnitude of incremental benefit claims, and costs.

Download DelveInsight's Irritable Bowel Syndrome Market report today and stay ahead in this rapidly evolving field. @ Irritable Bowel Syndrome Clinical Trials [https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Irritable Bowel Syndrome Market Report

* Coverage- 7MM
* Irritable Bowel Syndrome Companies- Redhill Biopharma, Forest Pharmaceuticals, Inc., Bausch Health, and others.
* Irritable Bowel Syndrome Therapies- rifaximin, eluxadoline, lubiprostone, linaclotide, and others.
* Irritable Bowel Syndrome Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Irritable Bowel Syndrome Unmet Needs, KOL's views, Analyst's views, Irritable Bowel Syndrome Market Access and Reimbursement

Download the report to understand which factors are driving Irritable Bowel Syndrome Market Trends @ Irritable Bowel Syndrome Market Trends [https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1 Key Insights

2 Report Introduction

3 Irritable Bowel Syndrome Market Overview at a Glance

4 Epidemiology and Market Methodology

5 Executive Summary of Irritable Bowel Syndrome

6 Disease Background and Overview

7 Epidemiology and Patient Population

8 Patient Journey

9 Key Endpoints in Irritable Bowel Syndrome Clinical Trials

10 Emerging Therapies

11 Marketed Therapies

12 Irritable Bowel Syndrome: The 7MM Analysis

13 Market Access and Reimbursement

14 KOL Views

15 SWOT Analysis

16 Unmet Needs

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=irritable-bowel-syndrome-treatment-market-size-in-the-7mm-was-usd-2000-million-in-2023-estimated-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.